Short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer

作者全名："Song, Rui; Liu, Li; Pan, Qingbo; Liu, Jin; Tan, Jiahe; Deng, Juan; Deng, Qin; Lin, Zijin; Chen, Min; Peng, Mingli; Ren, Hong; Ming, Jia"

作者地址："[Song, Rui; Pan, Qingbo; Chen, Min; Peng, Mingli; Ren, Hong] Chongqing Med Univ, Affiliated Hosp 2, Dept Infect Dis, Chongqing, Peoples R China; [Liu, Li; Deng, Juan; Deng, Qin; Lin, Zijin; Ming, Jia] Chongqing Med Univ, Affiliated Hosp 2, Dept Breast & Thyroid Surg, Chongqing, Peoples R China; [Liu, Jin] First Peoples Hosp Yibin, Dept Breast & Thyroid Surg, Yibin, Sichuan, Peoples R China; [Tan, Jiahe] Chongqing Med Univ, Dept Neurosurg, Affiliated Hosp 1, Chongqing, Peoples R China"

通信作者："Ren, H (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Infect Dis, Chongqing, Peoples R China.; Ming, J (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Breast & Thyroid Surg, Chongqing, Peoples R China."

来源：FRONTIERS IN IMMUNOLOGY

ESI学科分类：IMMUNOLOGY

WOS号：WOS:000880106100001

JCR分区：Q1

影响因子：7.3

年份：2022

卷号：13

期号：　

开始页：　

结束页：　

文献类型：Article

关键词：cancer; COVID-19; SARS-COV-2; vaccine; memory B cells

摘要："BackgroundThe aim of this study was to explore the short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer (ER). MethodsEighty-eight patients with ER cancer and 82 healthy controls who had completed a full course of inactivated or peptide-based SARS-CoV-2 vaccines were recruited. Adverse events (AEs) were recorded. Responses to receptor-binding domain IgG antibody (anti-RBD-IgG), neutralizing antibodies (NAbs) and RBD+ memory B cells (MBCs) were evaluated. ResultsApproximately 26.14% (23/88) of patients with ER cancer reported AEs within 7 days, which was comparable to that reported by healthy controls (24.39%, 20/82). Both the overall seroprevalence of anti-RBD-IgG and NAbs was obviously lower in the cancer group (70.45% vs. 86.59%, P < 0.05; 69.32% vs. 82.93%, P < 0.05, respectively). Anti-RBD-IgG and NAbs titers exhibited similar results, and dropped gradually over time. Patients with ongoing treatment had an attenuated immune response, especially in patients receiving active chemotherapy. The frequency of overall RBD+ MBCs was similar between the two groups, but the percentage of active MBCs was remarkably reduced in patients with ER cancer. Unlike antibody titers, MBCs responses were relatively constant over time. ConclusionInactivated and peptide-based COVID-19 vaccines were well tolerated, but with lower immunogenicity for ER cancer patients. More intensive antibody monitoring and timely booster immunization is recommended for patients with ER cancer presenting disordered subpopulations of RBD+ MBCs."

基金机构：National Science and Technology Major Project of China; Postgraduate research and innovation projects of Chongqing Municipal Education Commission; [2017ZX10202203-007]; [2017ZX10202203-008]; [2018ZX10302206-003]; [CYS20197]

基金资助正文："Funding This work is supported by the National Science and Technology Major Project of China (2017ZX10202203-007, 2017ZX10202203-008, 2018ZX10302206-003) and the Postgraduate research and innovation projects of Chongqing Municipal Education Commission (CYS20197)."